II Clinica Ostetrica Ginecologica, Università di Milano, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli, Regina Elena, Milan, Italy.
Eur J Cancer Prev. 2010 Nov;19(6):428-30. doi: 10.1097/CEJ.0b013e32833d9388.
The objective of this study was to analyse time-related aspects of the use of fertility drugs related to the risk of endometrial cancer using data from a case-control study conducted between 1992 and 2006 in Italy. The study included 454 cases (median age, 60 years; range, 18-79) with incident, histologically confirmed endometrial cancer and 908 female controls (median age, 61 years; range 19-79) admitted to the same network of hospitals as cases for a wide spectrum of acute, non-neoplastic conditions. Controls were frequency matched to cases with a 2:1 ratio for age and study centre. Information was collected by trained interviewers using a structured questionnaire. We calculated odds ratios (ORs) and the corresponding 95% confidence intervals (CI) using conditional logistic regression models adjusted for major relevant covariates. The OR of endometrial cancer for ever use of fertility drugs was 3.26 (95% CI, 1.07-9.95). The risk was higher for duration of use 12 months or more (OR=6.10; 95% CI, 0.96-38.6), time since last use 25 years or less before the interview (OR=5.30; 95% CI, 1.12-25.1), and for age at first use less than 30 years (OR=5.14; 95% CI, 1.13-23.4). The association was apparently stronger in ever-gravid (OR=6.50; 95% CI, 1.10-38.3) than in nulligravid (OR=2.83; 95% CI, 0.32-25.0) women. Our data support earlier findings of an increase in risk of endometrial cancer with duration of use of fertility drugs.
本研究旨在分析与生育药物使用相关的时间因素与子宫内膜癌风险之间的关系,研究数据来自于 1992 年至 2006 年在意大利开展的一项病例对照研究。研究共纳入 454 例(中位年龄 60 岁,范围 18-79 岁)经组织学证实的新发子宫内膜癌病例,以及 908 例(中位年龄 61 岁,范围 19-79 岁)因各种急性非肿瘤性疾病在同一医院网络中接受治疗的女性对照者。病例与对照以 2:1 的年龄和研究中心匹配。通过训练有素的调查员使用结构化问卷收集信息。我们采用条件逻辑回归模型,在模型中调整了主要相关协变量,计算了比值比(OR)及其 95%置信区间(CI)。使用生育药物的 OR 为 3.26(95%CI,1.07-9.95)。使用时间 12 个月或以上(OR=6.10;95%CI,0.96-38.6)、末次使用时间距离访谈时间 25 年或以内(OR=5.30;95%CI,1.12-25.1)、初次使用年龄小于 30 岁(OR=5.14;95%CI,1.13-23.4)的风险更高。在曾生育(OR=6.50;95%CI,1.10-38.3)的女性中,这种关联似乎比未生育(OR=2.83;95%CI,0.32-25.0)的女性更强。我们的数据支持生育药物使用时间与子宫内膜癌风险增加之间存在关联的早期发现。